Contact
Please use this form to send email to PR contact of this press release:
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
TO:
Please use this form to send email to PR contact of this press release:
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
TO: